Abstract
In a phase II study, daclizumab was given as single second-line agent to 62 patients with steroid-refractory acute graft-versus-host disease (aGVHD). Complete resolution of aGVHD was achieved in 68.8% of patients. This response rate was significantly associated with a lower number of involved organs and smaller extent of skin involvement. The 4-year event-free survival (EFS) was 54.6%. Grade > or =III aGVHD, > or =2 involved organs at baseline and patient age >18 years were independently associated with lower EFS. Daclizumab could be a suitable alternative treatment for aGVHD, particularly when limited to the skin or gastrointestinal tract.
MeSH terms
-
Acute Disease
-
Adolescent
-
Adult
-
Age Factors
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Child
-
Child, Preschool
-
Daclizumab
-
Female
-
Graft vs Host Disease / drug therapy*
-
Graft vs Host Disease / mortality
-
Graft vs Host Disease / pathology
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use*
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Infant
-
Male
-
Middle Aged
-
Prospective Studies
-
Remission Induction
-
Stem Cell Transplantation / adverse effects
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Daclizumab